ArticleCancers2020
Genetic Analysis Reveals a Significant Contribution of
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Multiscale Transcriptomic and Molecular Modeling Analyses Suggest DCPMU-Associated Epithelial Remodeling and Tumor Microenvironment Perturbation in Prostate Cancer.Current issues in molecular biology · 2026Article
- Exploratory Toxicogenomic Profiling Identifies Candidate DINCH-Responsive Genes Relevant to Prostate Cancer.International journal of molecular sciences · 2026Article
- From Plastics to Prognosis:Diagnostics (Basel, Switzerland) · 2026Article
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
- Hypercholesterolemia and the role of lipid metabolism gene CES1 in immune infiltration promote central nervous system relapse in acute myeloid leukemia.Frontiers in immunology · 2025Article
- Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.BMC medical genomics · 2024Article
- A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer.Frontiers in molecular biosciences · 2024Article
- Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation.American journal of cancer research · 2024Article
- Genetic Analysis Implicates Dysregulation ofInternational journal of environmental research and public health · 2022Article
- TNFRSF13B is a potential contributor to prostate cancer.Cancer cell international · 2022Article
- The Study of Cancer Susceptibility Genes.Cancers · 2021Article
- Enzyme-Responsive Materials as Carriers for Improving Photodynamic Therapy.Frontiers in chemistry · 2021Review
- Genetic Analysis Identifies the Role ofCancer genomics & proteomicsArticle
- Germline Variation in Notch Pathway and Survival After Androgen Deprivation Therapy in Prostate Cancer: ImplicatingCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
Abstract
The genes that influence prostate cancer progression remain largely unknown. Since the carboxylesterase gene family plays a crucial role in xenobiotic metabolism and lipid/cholesterol homeostasis, we hypothesize that genetic variants in carboxylesterase genes may influence clinical outcomes for prostate cancer patients. A total of 478 (36 genotyped and 442 imputed) single nucleotide polymorphisms (SNPs) in five genes of the carboxylesterase family were assessed in terms of their associations with biochemical recurrence (BCR)-free survival in 643 Taiwanese patients with prostate cancer who underwent radical prostatectomy. The strongest association signal was shown in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.